Amendments to the Specification

Please replace the paragraph at page 12, line 30 through page 13, line 3 with the following amended paragraph:

In a specific embodiment disclosed herein, the invention relates to the nucleic acid sequence of the human *TCL-1* gene. In a preferred, but not limiting, aspect of the invention, a human *TCL-1* cDNA sequence is that present in plasmid pAl1.5 as deposited with the ATCC and assigned ATCC Accession Number [[____]] 75923. Such a sequence can be cloned and sequenced, for example, as described Section 6, *infra*. The invention also relates to nucleic acid sequences hybridizable or complementary to the foregoing sequences or equivalent to the foregoing sequences in that the equivalent nucleic acid sequences also encode a TCL-1 protein product.

Please replace the paragraph at page 65, line 2 through 11 with the following amended paragraph:

Plasmid pAl1.5, containing a full-length *TCL-1* cDNA as an EcoRI insert into the pBluescript SK+ SK⁺ vector (Stratagene); and plasmid p20-7SE, containing a genomic sequence of *TCL-1* (including the 5' sequence shown in Figure 3B) as a SalI-EcoRI insert into the pBluescript SK⁺ vector; were both deposited on October 25, 1994, with the American Type Culture Collection, 1201 12301 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and were assigned Accession Nos. 75923 and 75924, respectively.